93 results about "Env Protein" patented technology

The invention discloses a method for displaying foreign protein by utilizing salmonella and application of the method, and belongs to the technical field of biological medicine. According to the invention, the SpyCatcher and an outer membrane protein Lpp-OmpA gene are fused and are expressed in salmonella, a recombinant strain is constructed, and the SpyCatcher is displayed on the surface of bacteria; the foreign protein gene and the SpyTag gene are fused and subjected to prokaryotic expression purification, and recombinant foreign protein is obtained; after the recombinant foreign protein and the recombinant salmonella are incubated, the foreign protein can be anchored on the surface of the salmonella through a SpyCatcher-SpyTag covalent bond. When the foreign protein is an antigen protein, the foreign protein is displayed on the surface of the attenuated bacterial vector, and a live vector vaccine can be prepared. The invention provides a novel universal antigen display method, overcomes the limitation of the traditional antigen display method on the protein size and conformation, and has a good application prospect in live vector vaccine construction.

The invention discloses an mRNA-LNPs Brucella vaccine, an expression vector and a preparation method thereof. The mRNA-LNPs Brucella vaccine comprises at least one of mRNA of an outer membrane protein BP26 and mRNA of an outer membrane protein Omp 25. According to the present invention, the antigen sequence is optimized, the prepared mRNA Brucella vaccine can stimulate the body to produce strong immunogenicity, and compared with the Brucella vaccine prepared before the sequence optimization, the antibody titer is significantly improved. A mouse immune experiment research result shows that high-titer IgG, IgG1 and IgG2a can be generated. Th1 type reaction, Th2 type reaction or mixed Th type reaction is successfully induced.

The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.

The invention discloses an acinetobacter baumannii outer membrane protein liposome vaccine as well as a preparation method and application thereof, and relates to the field of biological medicines. The acinetobacter baumannii outer membrane protein liposome vaccine is obtained by efficiently expressing the acinetobacter baumannii outer membrane protein through a genetic engineering means and combining the obtained multiple outer membrane proteins as antigens with a lipid mixture and an adjuvant, and the acinetobacter baumannii outer membrane protein liposome vaccine is proved to be capable of providing complete protection for mice challenged by lethal dose acinetobacter baumannii. Wherein the outer membrane protein loaded by the lipidosome realizes structural refolding, the protein immunogenicity is enhanced, and the lipidosome can reduce the toxicity of the outer membrane protein; omp38 + BauA + FimA may be an effective antigen combination for preventing acinetobacter baumannii infection; as a TLR2 agonist, Pam2CSK4 has a strong auxiliary effect on an acinetobacter baumannii liposome vaccine, can induce innate immune response activation, and provides a more comprehensive protection effect on a host.

The invention discloses an indirect ELISA (Enzyme-Linked Immunosorbent Assay) detection kit for distinguishing host infected Listeria monocytogenes and / or Listeria ivanovii. The coating antigens are respectively a recombinant listeria monocytogenes surface protein ActA, a serotype 4h listeria monocytogenes and listeria ivanovii common outer membrane protein SmcL and a listeria ivanovii specific outer membrane protein I-inlH, indirect ELISA methods are respectively established based on the three antigens, the three detection methods are combined to detect the content of the listeria monocytogenes, and the content of the listeria ivanovii can be detected. The levels of the ActA antibody, the SmcL antibody and the I-inlH antibody in a clinical serum sample can be effectively monitored, and the detection on the listeria monocytogenes caused by the listeria monocytogenes and / or the listeria ivanovii is realized. The kit is relatively high in sensitivity, strong in specificity and good in stability, and an effective method is provided for epidemiological investigation and diagnosis of listeria monocytogenes.

The invention discloses recombinant bacillus subtilis with the surface displaying Edwardsiella tarda outer membrane protein OmpA and vibrio cholerae enterotoxin CTB fusion protein, a construction method and application, spore capsid protein CotY serves as an anchor point, coding genes of OmpA and CTB are recombined into a genome of bacillus subtilis 168 in a homologous double cross mode, and the recombinant bacillus subtilis is obtained. The recombinant bacillus subtilis can be stably inherited in the bacillus subtilis and displays edwardsiella tarda outer membrane protein OmpA and vibrio cholerae enterotoxin CTB on the spore surface; after fishes and mammals orally immunize the Edwardsiella tarda, the survival time and the survival rate of bodies infected with the Edwardsiella tarda are remarkably improved; the recombinant bacillus subtilis is used as an oral vaccine type micro-ecological immune preparation for preventing and treating Edwardsiella tarda infection of fishes and mammals, the immune procedure is remarkably simplified, the immune stress is reduced, the labor cost is saved, the effective action concentration in the intestinal tract is ensured, and the organism is induced to generate specific immune response.

The invention relates to antigen-binding proteins specifically binding Acinetobacter cells, more specifically, wherein said binding occurs through targeting a binding site of Outer membrane protein 25 (Omp25) exposed on the surface of said pathogenic Acinetobacter cells in capsulated and non- capsulated form. More specifically, the invention relates to a family of immunoglobulin single variable domains (ISVDs) capable of specifically binding the Acinetobacter baumannii Outer membrane protein 25 (Omp25) at an epitope located in the surface-exposed regions. The invention further relates to fusions of said antigen-binding proteins as multivalent, multispecific or functional fusions with further moieties, and their use in functionalized targeting of A. baumannii, as a scavenger or to induce killing activity. More particular said antigen-binding proteins or fusions are provided as a tool for detection of Acinetobacter, or for depletion of bacterial cells from a sample upon binding. Finally, the invention relates to said antigen-binding proteins for use as a diagnostic or as a medicine, preferably in prevention or treatment of Acinetobacter baumannii infection.

The invention relates to a recombinant expression vector for synthesizing outer membrane protein of cyanidin-3-O-glucoside, a recombinant microorganism and a preparation method of the recombinant microorganism. The recombinant expression vector contains a gene sequence for coding the outer membrane protein. The outer membrane protein is used for constructing a recombinant expression vector and a recombinant microorganism, efflux transport of cyanidin-3-O-glucoside is promoted, and the yield of cyanidin-3-O-glucoside is increased.

Disclosed are a recombinant interferon drug targeting a conserved HIV gp41 subunit membrane-proximal external region (MPER) and a use thereof. Specifically, disclosed is a targeted interferon fusion protein ZP-IC, comprising a 10E8 antibody or an antigen-binding fragment thereof, and an integrated interferon α, wherein the 10E8 antibody or the antigen-binding fragment thereof is linked to the integrated interferon α by means of a linker. In the present invention, the 10E8 antibody capable of identifying a highly conserved gp41 subunit MPER of an HIV envelope glycoprotein is used as a targeting tool for the integrated interferon. Therefore, a target exposed by a conformational change of a viral envelope protein during the infection of a cell can be accurately identified, viral infection is prevented, and a neutralizing effect is exerted; and in addition, a carried interferon molecule can more effectively bind to an interferon receptor on a cell around the HIV virus and achieve an antiviral role. Experiments have demonstrated that the ZP-IC has excellent antiviral activity and the capability of inhibiting an overwhelming majority of HIV strains across a broad spectrum.

The invention discloses a novel group B epidemic cerebrospinal meningitis outer membrane protein bifunctional vector, relates to the technical field of biopharmaceutical processes, and discloses a group B epidemic cerebrospinal meningitis outer membrane protein bifunctional vector and application thereof in epidemic cerebrospinal meningitis combined vaccinis.The bifunctional vector is human H factor binding protein fHbp and comprises two recombinant proteins BA and BB, the amino acid sequences of the amino acid sequences are respectively SEQ ID No. 62 and SEQ ID No. 63; the BA protein and the group A capsular polysaccharide are coupled to form a group A conjugate vaccine, the BB protein and the group C capsular polysaccharide are coupled to form a group C conjugate vaccine, the group A conjugate vaccine and the group C conjugate vaccine are mixed to form a group ABC triple vaccine, and each dose of the vaccine contains 40 micrograms of group A polysaccharide and 40 micrograms of group C polysaccharide, 160 micrograms of BA / BB protein and 1.0 mg of aluminum adjuvant; bA and BB proteins are expressed through escherichia coli and are subjected to high-pressure homogeneous crushing and anion exchange chromatography purification, and the purity is greater than or equal to 95%; the triple vaccine provided by the invention can simultaneously induce immune responses to group A, group B and group C meningococcal, the serum sterilization titer after first immunization is greater than or equal to 1: 32, and the titer after three immunization is maintained for more than 56 days.

The invention belongs to the technical field of genetic engineering, and particularly relates to construction and application of genetically engineered bacteria for producing PQQ. According to the invention, Escherichia coli K-12 MG1655 is used as a chassis cell, and genes pqqA and pqqBCDE, which are used for controlling the source of Gluconobacter oxydans 621H by a PT7 promoter, are integrated on a genome; performing copy number and promoter optimization on the pqqA gene, the pqqB gene, the pqqC gene, the pqqD gene and the pqqE gene in the pqq gene cluster; the method comprises the following steps: overexpressing and coding a metalloproteinase subunit TldD gene tlDd, and knocking out a coding DNA (Deoxyribose Nucleic Acid) to combine with a transcription dual-regulatory factor IscR gene iscR; enhancing the coding of the outer membrane protein A gene ompA; overexpressing a quinone protein glucose dehydrogenase coding gene gcd; the S-adenosylmethionine synthetase coding gene metK is integrated, and the efficient synthesis of the PQQ is realized through the method.

This invention discloses an antigen and vaccine preparation based on dominant Brucella epitopes, and their application, belonging to the field of recombinant subunit vaccine technology. The antigen is composed of CTL epitopes, HTL epitopes, and B-cell epitopes tandemly, and its amino acid sequence is shown in SEQ ID NO.1. Based on screened dominant CTL epitopes, HTL epitopes, and B-cell epitopes of the Omp25 and Omp31 outer membrane proteins, this invention constructs a novel antigen fusion polypeptide. The vaccine prepared based on this polypeptide effectively activates a significant dual immune response, enhancing cellular immunity while inducing the body to produce high levels of specific antibodies. It also provides good protection against organ damage caused by bacterial infection, offering better immune response and protective efficacy against Brucella, laying the foundation for the development of Brucella recombinant subunit vaccines.

The present disclosure provides recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment. Embodiments include the administration of the fusion proteins to patients having a disease or a disorder with the intention of mitigating and / or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and / or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in ALS patients associated with the condition or disease. Accordingly, “treatment” generally means both therapeutic treatment and prophylactic or preventative measures. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, e.g., by a decrease or elimination of symptoms associated with ALS, and / or by a decrease in the duration of such symptoms.

The present disclosure provides recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment. Embodiments include the administration of the fusion proteins to patients having a disease or a disorder with the intention of mitigating and / or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and / or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in ALS patients associated with the condition or disease. Accordingly, "treatment" generally means both therapeutic treatment and prophylactic or preventative measures. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, e.g., by a decrease or elimination of symptoms associated with ALS, and / or by a decrease in the duration of such symptoms.

The invention belongs to the technical field of molecular biology, and discloses a truncated outer membrane protein of klebsiella pneumoniae and application thereof. The invention provides an outer membrane protein Lol B of klebsiella pneumoniae, which can be used for immunizing to induce a protective antibody aiming at various serotypes of klebsiella pneumoniae and killing the klebsiella pneumoniae. Specifically, the outer membrane protein Lol B immune serum can efficiently kill Klebsiella pneumoniae, and when a mouse immunized by the outer membrane protein Lol B immune serum is attacked by K1, K2 and K6 serotype Klebsiella pneumoniae, the mouse can be completely protected to survive, and the trend of weight loss of the mouse is remarkably reduced. Therefore, the outer membrane protein Lol B provided by the invention has a clinical application value for preventing and treating klebsiella pneumoniae infection.

Antibodies and other molecules including an antigen binding region of an antibody that immunospecifically binds to a surface unit or a transmembrane unit of a Human endogenous retrovirus-K (HERV-K) Env protein are provided. The antibodies and other molecules typically include six complementarity determining regions (CDRs). In preferred forms the antibodies and other molecules immunospecifically bind to the amino acid sequence SEQ ID NO:223 and / or 224. Chimeric antigen receptors (CAR) formed using the provided antibodies are also provided, as are cell expressing the CAR. Methods of detecting HERV-K Env, and use thereof of various other methods such as diagnostic methods are also provided. Method of treatment for HERV-K Env protein-related diseases and disorders are also provided.

The invention relates to a Sebastes schlegeli endogenous retrovirus envelope protein Penv, a lentiviral vector and application thereof, and belongs to the field of genetic breeding of molecular biology, and the amino acid sequence of the envelope protein Penv is as shown in SEQ ID NO.1. The invention further provides an in-vitro assembly system, a transformant and a kit containing membrane fusion protein particles and lentiviral particles of the envelope protein Penv and application of the envelope protein Penv. VSVG protein is replaced with Penv protein from sclerobone fish, so that the transduction efficiency of the lentiviral particles to sclerobone fish cells is effectively improved, and the transduction efficiency of the lentiviral particles to the sclerobone fish cells is improved. And efficient gene delivery is realized. Meanwhile, as the endogenous Env protein, the Env protein overcomes the immunological rejection of a host to the exogenous Env protein, and also has the potential of in-vivo application.

The present invention provides compositions and methods of inducing an immune response in a subject in need thereof, comprising administering to the subject an immunologically-effective amount of a live Salmonella typhi vector comprising a heterologous antigen from a pathogen, wherein the heterologous antigen comprises an outer membrane protein, an antigenic fragment thereof or a variant thereof, wherein the antigen is delivered to a mucosal tissue of the subject by an outer membrane vesicle.

Implementations of an anti-tick vaccine composition may include one or more conserved tick proteins from a tick species; and one or more conserved outer membrane proteins of an endosymbiont of the tick species.

The invention discloses a preparation method and application of a vibrio outer membrane protein A multi-epitope antigen and a recombinant antigen thereof, and is characterized in that a protein multi-epitope antigen sequence synthesized by outer membrane proteins of vibrio splendidus, vibrio parahaemolyticus and vibrio alginolyticus is designed by utilizing a multi-epitope technology, and the amino acid sequence of the protein multi-epitope antigen sequence is shown as SEQ ID NO.4; the preparation method of the multi-epitope recombinant antigen comprises the following steps: synthesizing a multi-epitope gene according to a multi-epitope antigen amino acid sequence, connecting the multi-epitope gene to a pET-28a (+) vector, transforming a plasmid containing the multi-epitope gene into a protein expression type competent cell, screening out positive clones, and performing protein expression; the method comprises the following steps: carrying out protein purification by using affinity chromatography to obtain a multi-epitope recombinant antigen, further preparing a multi-epitope antibody by using the multi-epitope recombinant antigen, and detecting whether a to-be-detected sample solution contains vibrio or not by using the multi-epitope antibody as a labeled protein and using a trace thermophoresis technology, so that the method has the advantages of high detection speed and strong specificity.

The invention particularly relates to a sebastes schlegeli endogenous retrovirus envelope protein percomORF, a lentiviral vector and application of the sebastes schlegeli endogenous retrovirus envelope protein percomORF and the lentiviral vector, and belongs to the field of genetic breeding of molecular biology, and the envelope protein percomORF has an amino acid sequence as shown in SEQ ID NO.1. The invention also covers a membrane fusion protein particle constructed based on the protein, a system for in-vitro assembly of lentivirus particles, a corresponding transformant and a matched kit. By replacing conventional VSVG protein with percomORF protein from sclerobone fish, the infection and transduction efficiency of lentivirus on sclerobone fish cells can be effectively enhanced, and more efficient gene delivery is realized. Besides, the protein belongs to host endogenous Env protein and is beneficial to avoiding immunological rejection caused by introduction of foreign protein, so that the protein has good potential in in-vivo gene delivery application.

Implementations of an anti-tick vaccine composition may include one or more conserved tick proteins from a tick species; and one or more conserved outer membrane proteins of an endosymbiont of the tick species.

The present disclosure provides recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment. Embodiments include the administration of the fusion proteins to patients having a disease or a disorder with the intention of mitigating and / or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and / or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in ALS patients associated with the condition or disease. Accordingly, “treatment” generally means both therapeutic treatment and prophylactic or preventative measures. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, e.g., by a decrease or elimination of symptoms associated with ALS, and / or by a decrease in the duration of such symptoms.

The application discloses a novel group B meningococcal outer membrane protein bifunctional carrier, relates to the technical field of biopharmaceutical processes, and discloses a group B meningococcal outer membrane protein bifunctional carrier and application of the bifunctional carrier in a meningitis combined vaccine. The bifunctional carrier is human H factor binding protein fHbp, and comprises two kinds of recombinant proteins BA and BB, and the amino acid sequences of the two kinds of recombinin proteins are SEQ ID No. 62 and SEQ ID No. 63 respectively. The BA protein is coupled with group A capsule polysaccharide to form a group A combined vaccine, the BB protein is coupled with group C capsule polysaccharide to form a group C combined vaccine, and the two are mixed to form a group ABC triple vaccine. Each dose of the triple vaccine contains 40 μg of group A / C polysaccharide, 160 μg of BA / BB protein in total and 1.0 mg of aluminum adjuvant. The BA and BB proteins are expressed by E. coli, are broken by high-pressure homogenization, and are purified by anion exchange chromatography, and the purity is greater than or equal to 95%. The triple vaccine can simultaneously induce immune responses to groups A, B and C of meningitis, the serum bactericidal titer is greater than or equal to 1:32 after primary immunization, and the titer is maintained for more than 56 days after three immunizations.

The application discloses a liposome vaccine of Acinetobacter baumannii outer membrane protein and a preparation method and application thereof, and relates to the field of biological medicines. The application efficiently expresses the Acinetobacter baumannii outer membrane protein through a genetic engineering method, and obtains a liposome vaccine of Acinetobacter baumannii outer membrane protein by combining the obtained various outer membrane proteins as antigens with a lipid mixture and an adjuvant. It is verified that the vaccine can provide complete protection for mice attacked by a lethal dose of Acinetobacter baumannii. In the application, the outer membrane protein loaded in the liposome is re-folded in structure, the immunogenicity of the protein is enhanced, and the liposome can reduce the toxicity of the outer membrane protein. Omp38+BauA+FimA can be an effective antigen combination for preventing Acinetobacter baumannii infection. Pam2CSK4 as a TLR2 agonist has a strong auxiliary effect on the liposome vaccine of Acinetobacter baumannii, and can induce the activation of an innate immune response, thereby providing more comprehensive protection for a host.

The invention relates to a rapid detection reagent for a yellow fever virus antibody and a preparation method of the rapid detection reagent, and belongs to the technical field of biological detection. The detection reagent comprises a magnetic nanoparticle capture reagent and immunochromatography test paper formed by sequentially overlapping a sample pad, a glass fiber pad, a nitrocellulose detection membrane and a water absorption pad and adhering to a bottom lining card, the nitrocellulose detection membrane is coated with a quality control line of a rabbit anti-E protein polyclonal antibody and a detection line of yellow fever virus outer membrane E protein, and the magnetic nanoparticle capture reagent is ferroferric oxide magnetic nanoparticles labeled by the yellow fever virus outer membrane E protein. The reagent provided by the invention is prepared from the prepared yellow fever virus outer membrane E protein antigen, can be effectively used for detecting the yellow fever virus antibody, is high in detection result sensitivity, strong in specificity and reliable and stable in detection result, can judge the detection result through visual inspection, can also perform judgment without an instrument, and is convenient to use.

The application belongs to the field of animal bacteriology and molecular biology technology, and relates to preparation of a hybridoma cell and application thereof. A monoclonal antibody is prepared through intracellular Lawsonia intracellularis outer membrane protein OmpA expressed by prokaryotes, and IFA, WB and blocking ELISA and other immunological detection methods for detecting or diagnosing Lawsonia intracellularis are established through the expressed intracellular Lawsonia intracellularis outer membrane protein OmpA and the prepared monoclonal antibody. The blocking ELISA for detecting serum antibodies of Lawsonia intracellularis can detect serum samples of suspected Lawsonia intracellularis infection from different species, and does not exist cross reaction with positive serum of common pig pathogens, has high sensitivity and specificity, is good in repeatability, and is suitable for high-throughput detection of serum samples.

The invention belongs to the field of animal vaccines, and discloses an outer membrane protein antigen composition aiming at multiple serotypes of laisseria parasuis and application of the outer membrane protein antigen composition. The applicant carries out proteomics analysis on 4-type, 5-type and 13-type clinical isolated strains of serotypes of laisseria parasuis with high toxicity and good immunogenicity, eight vaccine antigen proteins are screened out, and further screening finds that the protection effect of the combination of the five antigen proteins Pal, Aida, EspP2, LppA and FLK6204400 on weaned piglets is better than that of the combination of the eight proteins. And then the proportions of the antigen components are explored, so that the protective force of the obtained raisseria parasuis outer membrane protein antigen composition with the optimal proportion on raisseria parasuis serotype 4, serotype 5 and serotype 13 reaches 100%.

According to the invention, dominant antigen epitopes of main outer membrane proteins OspA, OspB and OspC of borrelia burgdorferi are screened out, and a multi-epitope fusion vaccine containing the epitopes and application are constructed. The vaccine design not only improves the specificity and immunogenicity of the antigen. Compared with a traditional antigen epitope screening and construction strategy, the method has the advantages that the cycle is shortened, the cost is reduced, meanwhile, the limitations of many and complex antigens, large toxic and side effects and the like of a traditional vaccine are overcome, the operation process is simplified, the method is more suitable for large-scale epitope screening, popularization and application, and a new thought and strategy are provided for research and development of borrelia burgdorferi vaccines.

The application discloses a recombinant bacillus subtilis of surface display of a fusion protein of Edwardsiella tarda outer membrane protein OmpA and Vibrio cholerae enterotoxin CTB, a construction method and application. A homologous double cross recombinant of coding genes of OmpA and CTB is carried out into a genome of the bacillus subtilis 168 by taking the spore coat protein CotY as an anchor point, so that the recombinant bacillus subtilis capable of stably inheriting in the bacillus subtilis and displaying the Edwardsiella tarda outer membrane protein OmpA and the Vibrio cholerae enterotoxin CTB on a spore surface is obtained. After fish and mammals orally immunize the bacillus subtilis, the survival time and survival rate of the fish and mammals after infection of the Edwardsiella tarda are obviously improved. The recombinant bacillus subtilis is used as an oral vaccine type micro-ecological immunization preparation for preventing and treating the Edwardsiella tarda infection of the fish and mammals, so that the immunization procedure is obviously simplified, the immunization stress is reduced, the labor cost is saved, the effective concentration in the intestinal tract is ensured, and the specific immune response of the body is induced.